TLDR
- Polymarket and Kalshi now offer contracts tied to health decisions, including CDC vaccine changes.
- A Johns Hopkins expert says FDA and trial markets reward people who leak private information.
- Critics warn trial participants and drug companies could act to sway results.
- Kalshi says clinical trial markets could make drug development more transparent.
- Kalshi faces a tribal lawsuit, and Polymarket has announced large layoffs.
Polymarket and Kalshi now let users trade contracts tied to health decisions. Users can bet on events such as whether the US Centers for Disease Control and Prevention (CDC) will change its vaccine recommendations.
The markets also cover Food and Drug Administration (FDA) decisions and clinical trial outcomes. Some health experts say this gives people who hold private information a new way to profit from it.
Insider Information Worries
Matthew Eisenberg, professor and chair of health policy and management at the Johns Hopkins Bloomberg School of Public Health, said he was not surprised by the move. Both platforms list contracts on almost any event with an outcome that can be checked.
He said markets on FDA decisions and trial results give a reason to cash in to people with access to confidential details. This group includes agency reviewers, trial investigators and legislative staff.
Platforms may add safeguards, such as checking a user’s employer when they sign up. Still, he said the bigger risk may be people leaking insider information for money, rather than bribery.
Critics also warn the markets could change how drugs are tested. Trial participants might change their behavior on purpose to affect results.
Drug companies could also shift the timing of trials to move predictions. Either case could affect how new medicines are studied and approved.
Kalshi spokesperson Dani Lever offered a different view. Lever said markets on clinical trials and drug approvals could make the drug development process more transparent.
According to Lever, the platform’s clinical trial markets aim to fix a structural problem in drug development. Lever said public prediction markets could help get past these barriers.
Gaps in Oversight
Lia Nower, professor and director of the Center for Gambling Studies at Rutgers University, said prediction markets work much like regulated gambling. However, she said they remain mostly unregulated and called the current landscape a “wild, wild west.”
She said the US has no federal body that sets limits or basic guidelines for states on gambling. She also pointed out that the National Institutes of Health has no research centers focused on gambling, unlike those for alcohol and substance abuse.
She called on federal authorities to step in with stronger oversight and regulation. In her view, the current setup leaves too many gaps.
Prediction markets describe themselves as financial derivatives rather than bets. This places them under federal commodities laws, overseen by the US Commodity Futures Trading Commission (CFTC).
As a result, the platforms are not covered by state gambling rules. Several states have sued these companies, arguing the platforms act as gambling sites.
Kalshi also faces a separate lawsuit from the Alabama-Quassarte Tribal Town over its new prediction market app, PokkeTrades. The case centers on a deal between Kalshi and Michael Yargee to build the app. The tribe claims Yargee did not have the authority to represent it.
Polymarket, meanwhile, has announced large layoffs as part of a reorganization. The cuts come as both platforms expand into health-related contracts.
